201 related articles for article (PubMed ID: 18465140)
1. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
Mundhenke C; Weigel MT; Sturner KH; Roesel F; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Hilpert F; Jonat W; Maass N
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1397-405. PubMed ID: 18465140
[TBL] [Abstract][Full Text] [Related]
2. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2008 Jan; 108(1):182-90. PubMed ID: 18028988
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
[TBL] [Abstract][Full Text] [Related]
6. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
8. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
[TBL] [Abstract][Full Text] [Related]
12. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
Caudell JJ; Deavers MT; Slomovitz BM; Lu KH; Broaddus RR; Gershenson DM; Ramondetta LM
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):167-70. PubMed ID: 15894930
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
17. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
18. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.
Weigel MT; Dahmke L; Schem C; Bauerschlag DO; Weber K; Niehoff P; Bauer M; Strauss A; Jonat W; Maass N; Mundhenke C
BMC Cancer; 2010 Aug; 10():412. PubMed ID: 20691121
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
